Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein angel homolog 2 (ANGEL2) is a divergent member of the CCR4 family of deadenylases, functioning as an RNA phosphatase rather than a traditional deadenylase. ANGEL2 catalyzes the conversion of 2′,3′-cyclic phosphates on RNA molecules into 2′,3′-hydroxyl groups, a reaction required for proper tRNA maturation, recycling during cellular stress, and the unconventional splicing of select mRNAs such as X-box binding protein 1 (XBP1). Rather than shortening poly(A) tails like classical deadenylases, ANGEL2 specializes in preparing RNA ends for ligation and maturation. This activity supports essential RNA processing functions in both the mitochondrion and cytoplasm. Epigenetic dysregulation of ANGEL2 has been implicated as a biomarker in cervical carcinogenesis, highlighting its clinical relevance despite the absence of direct drug interactions or therapeutic targeting at present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein angel homolog 2 (ANGEL2).